Lung Cancer Clinical Trials in Maryland

Showing 421-440 of 718 trials

Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)

NCT00600015

This trial will investigate the use of the newer targeted agents erlotinib and sorafenib in patients with stage IIIB or stage IV NSCLC who have received 1-2 prior chemotherapy regimens. Patients will be randomized to receive erlotinib (150 mg/day) and sorafenib (400 mg twice daily), or erlotinib (150 mg/day) and a placebo.

Non-Small Cell Lung Cancer

SCRI Development Innovations, LLC166 participantsStarted Feb 2008

Fort Myers, Florida, United States • Gainesville, Georgia, United States • Marietta, Georgia, United States +13 more locations

UNKNOWNPhase 1/217 miles

PEN-866 in Patients With Advanced Solid Malignancies

NCT03221400

Protocol PEN-866-001 is an open-label, multi-center, first-in-human Phase 1/2a study evaluating PEN-866 in patients with advanced solid malignancies whose disease has progressed after treatment with previous anticancer therapies.

CarcinomaEndometrial AdenocarcinomaNeoplasms+16 more

Tarveda Therapeutics340 participantsStarted Aug 2017

Springdale, Arkansas, United States • Denver, Colorado, United States • Fort Myers, Florida, United States +13 more locations

Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)

PEN-866 in Patients With Advanced Solid Malignancies

Lung Cancer Trials in Other Cities

A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer

First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies

Cardiac MRI Biomarker Testing (GCC 1618)

A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604)

Phase I/II Study of PDR001 in Patients With Advanced Malignancies

PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies

A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)

A Study of PLX2853 in Advanced Malignancies.

A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection)

Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases

Phase 3 Study of Tavocept Versus Placebo in Patients With Newly Diagnosed or Relapsed Advanced Primary Adenocarcinoma of the Lung Treated With Docetaxel or Paclitaxel Plus Cisplatin

A Study of LY3023414 in Participants With Advanced Cancer

Registrational Trial to Compare Effectiveness of Two Digital Software Medical Devices as Adjunctive Oncology Treatment

NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine

Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC

Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors

First-Line Treatment of A Comparison of 2 Treatments in Elderly Patients With Advanced NSCLC

REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer

Other Conditions in Maryland